- Home
- TRMD vs BEAM Comparison
TRMD vs BEAM Comparison
Compare TRMD & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- BEAM
- Stock Information
- Founded
- TRMD 1889
- BEAM 2017
- Country
- TRMD United Kingdom
- BEAM United States
- Employees
- TRMD N/A
- BEAM N/A
- Industry
- TRMD Marine Transportation
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRMD Consumer Discretionary
- BEAM Health Care
- Exchange
- TRMD Nasdaq
- BEAM Nasdaq
- Market Cap
- TRMD 1.9B
- BEAM 1.8B
- IPO Year
- TRMD N/A
- BEAM 2020
- Fundamental
- Price
- TRMD $16.21
- BEAM $17.25
- Analyst Decision
- TRMD Buy
- BEAM Strong Buy
- Analyst Count
- TRMD 1
- BEAM 11
- Target Price
- TRMD $23.00
- BEAM $48.90
- AVG Volume (30 Days)
- TRMD 593.4K
- BEAM 2.2M
- Earning Date
- TRMD 05-08-2025
- BEAM 05-06-2025
- Dividend Yield
- TRMD 31.43%
- BEAM N/A
- EPS Growth
- TRMD N/A
- BEAM N/A
- EPS
- TRMD 4.73
- BEAM N/A
- Revenue
- TRMD $1,444,200,000.00
- BEAM $63,578,000.00
- Revenue This Year
- TRMD N/A
- BEAM N/A
- Revenue Next Year
- TRMD N/A
- BEAM $6.32
- P/E Ratio
- TRMD $3.42
- BEAM N/A
- Revenue Growth
- TRMD N/A
- BEAM N/A
- 52 Week Low
- TRMD $13.60
- BEAM $13.53
- 52 Week High
- TRMD $40.47
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- TRMD 47.61
- BEAM 42.35
- Support Level
- TRMD $16.24
- BEAM $15.51
- Resistance Level
- TRMD $17.40
- BEAM $20.90
- Average True Range (ATR)
- TRMD 0.40
- BEAM 1.32
- MACD
- TRMD 0.14
- BEAM -0.02
- Stochastic Oscillator
- TRMD 41.95
- BEAM 32.28
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.